Table 3.
Disease and treatment-related characteristics
| Variables | Indirect economic burden per capita ($#) | N (%) | Statistics* | P |
|---|---|---|---|---|
| Disease and treatment-related characteristics | ||||
| Pathological type | ||||
| Squamous carcinoma | 947 | 217 (35.5) | 42,606.5 | 0.939 |
| Non-squamous carcinoma | 1670 | 394 (64.5) | ||
| Clinical stage | ||||
| Locally advanced (IIIB–IIIC) | 809 | 201 (32.9) | 41,004.5 | 0.913 |
| Metastatic (IV)a | 1709 | 410 (67.1) | ||
| Progression | ||||
| No | 708 | 357 (58.4) | 45,049 | 0.88 |
| Yes | 2404 | 254 (41.6) | ||
| Therapy | ||||
| Immunotherapy | 2080 | 209 (34.2) | 37,050 | 0.007 |
| Others | 1066 | 402 (65.8) | ||
| Gene drive | ||||
| No | 1491 | 560 (91.7) | 15,996 | 0.109 |
| Yesb | 555 | 51 (8.3) | ||
| Duration of disease since diagnosis (months) | – | 16.36 ± 24.21 | 0.0817 | 0.043 |
| Hospitalization frequency | – | 8.87 ± 9.70 | 0.0517 | 0.207 |
*Including the statistics W-value of Wilcoxon rank-sum test, H-value of Kruskal–Wallis test, and rs-value of Spearman’s rank correlation analysis
#Resource: Average annual exchange rate in 2021 from China Foreign Exchange Trade System (https://www.chinamoney.com.cn/chinese/bkccpr/)
aThe indirect cost per capita in metastatic stage may have contributed person-time to both locally advanced stage and metastatic stage
bPositive driver genes include HER2, KRAS, BRAF, BRCA1/2, ATM, TP53, RET, TET1, etc.